urinary human chorionic gonadotrophin
Biologicalexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
3
Earliest trial started Sep 1, 2012 (NCT01653743)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- msj-0011
- urinary human chorionic gonadotrophin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06896617 | Phase 4 | Feb 1, 2025 | University of Barcelona |
| NCT03660813 | N/A | Jul 1, 2018 | Tel Aviv University |
| NCT04008966 | Phase 4 | Jul 20, 2016 | Cairo University |
| NCT02355925 | Phase 3 | Oct 1, 2014 | Royan Institute |
| NCT00415766 | Phase 4 | Jun 1, 2013 | Eugonia |
| NCT01653743 | Phase 3 | Sep 1, 2012 | Merck KGaA, Merck Serono |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Eugonia | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Merck KGaA | For profit | 1 | 1 | 1 | 2012 |
| Merck Serono | For profit | 1 | 0 | 1 | 2012 |
| Royan Institute | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Barcelona | Academic/Hospital | 1 | 1 | 1 | 2025 |
7 organizations
Page 1 / 1